#multiple sclerosis

A study of more than 617,000 people adds mechanistic detail to the growing case that Epstein-Barr virus helps drive multiple sclerosis by altering immune-cell behavior and activating risk-related genes.

Data presented at the American Academy of Neurology meeting suggest Roche’s multiple sclerosis pill outperformed Aubagio on relapse timing, while raising monitoring concerns around liver toxicity.

A major new study tracking MS in England from 2000 to 2020 finds that recorded prevalence has more than doubled — but the increase reflects better diagnosis and longer survival rather than an underlying epidemic, painting a complex picture of progress and persistent challenge in one of neurology's most studied diseases.